These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10099082)

  • 1. Pharmacokinetics of azidothymidine and its major metabolite glucuronylazidothymidine in hemophiliacs coinfected with human immunodeficiency virus and chronic hepatitis C.
    Rockstroh JK; Reichel C; Hille H; Oldenburg J; Brackmann HH
    Am J Ther; 1998 Nov; 5(6):387-91. PubMed ID: 10099082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.
    Singlas E; Pioger JC; Taburet AM; Colin JN; Fillastre JP
    Clin Pharmacol Ther; 1989 Aug; 46(2):190-7. PubMed ID: 2758728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian multicenter azidothymidine trial: AZT pharmacokinetics.
    Child S; Montaner J; Tsoukas C; Fanning M; Le T; Wall RA; Ruedy J
    J Acquir Immune Defic Syndr (1988); 1991; 4(9):865-70. PubMed ID: 1895207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of zidovudine in patients with liver cirrhosis.
    Taburet AM; Naveau S; Zorza G; Colin JN; Delfraissy JF; Chaput JC; Singlas E
    Clin Pharmacol Ther; 1990 Jun; 47(6):731-9. PubMed ID: 2357867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease.
    Kimmel PL; Lew SQ; Umana WO; Li PP; Gordon AM; Straw J
    Blood Purif; 1995; 13(6):340-6. PubMed ID: 8821198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports.
    Garraffo R; Cassuto-Viguier E; Barillon J; Chanalet L; Lapalus P; Duplay H
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):535-9. PubMed ID: 2613387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.
    Mancuso ME; Rumi MG; Aghemo A; Santagostino E; Puoti M; Coppola A; Colombo M; Mannucci PM
    J Thromb Haemost; 2009 Dec; 7(12):1997-2005. PubMed ID: 19799716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs.
    Ghany MG; Leissinger C; Lagier R; Sanchez-Pescador R; Lok AS
    Dig Dis Sci; 1996 Jun; 41(6):1265-72. PubMed ID: 8654162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients.
    Steffe EM; King JH; Inciardi JF; Flynn NF; Goldstein E; Tonjes TS; Benet LZ
    J Acquir Immune Defic Syndr (1988); 1990; 3(7):691-4. PubMed ID: 2352121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C.
    Eyster ME; Sanders JC; Battegay M; Di Bisceglie AM
    Dig Dis Sci; 1995 Jul; 40(7):1583-8. PubMed ID: 7628288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection.
    Morse GD; Olson J; Portmore A; Taylor C; Plank C; Reichman RC
    Antiviral Res; 1989 Mar; 11(2):57-65. PubMed ID: 2729955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats.
    Mays DC; Dixon KF; Balboa A; Pawluk LJ; Bauer MR; Nawoot S; Gerber N
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1261-70. PubMed ID: 1762074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection.
    Lesens O; Deschênes M; Steben M; Bélanger G; Tsoukas CM
    J Infect Dis; 1999 May; 179(5):1254-8. PubMed ID: 10191232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV.
    Rockstroh JK; Spengler U; Sudhop T; Ewig S; Theisen A; Hammerstein U; Bierhoff E; Fischer HP; Oldenburg J; Brackmann HH; Sauerbruch T
    Am J Gastroenterol; 1996 Dec; 91(12):2563-8. PubMed ID: 8946987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs.
    Hayashi K; Fukuda Y; Nakano I; Katano Y; Yokozaki S; Toyoda H; Takamatsu J; Hayakawa T
    Haemophilia; 2000 Nov; 6(6):677-81. PubMed ID: 11122395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.
    Ruhnke M; Bauer FE; Seifert M; Trautmann M; Hille H; Koeppe P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2153-8. PubMed ID: 8257138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azidothymidine (AZT) in the treatment of symptomatic HIV-1-infected hemophiliacs.
    Eichinger S; Pabinger I; Hartl H; Stain C; Mayerhofer S; Schweiger C; Kier P; Schwarzinger I; Kyrle PA; Lechner K
    Thromb Haemost; 1990 Aug; 64(1):108-12. PubMed ID: 1980381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
    Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR
    Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.